Oral Anticoagulation and the Novel Oral Anticoagulants (NOACs):Where Are We at Midterm?

Academic Content

Program Overview

Faculty Presentations

Introduction Deepak L. Bhatt Elaine Hylek

Video Roundtable

Current Activity

Elaine Hylek, MD, MPH, Boston University School of Medicine, Boston, Massachusetts

NOACs in Clinical Care NOACS Prevention Data NOACS: Major Bleeding Meta-Analysis ESC 2012 Guidelines Update Garfield Registry Prophylaxis vs Anticoagulation Clinical Trial: Major Bleeding Benefit and Risk Bleeding Risk Score Consensus Statements CHA2DS2-VASc Bleeding Risk Score Circulation Article Patient Age vs TTR NOACs vs Warfarin NOACS & Renal Dysfunction EHRA NOACs Practical Guide Procedural Management NOACs Bleeding Management Life-threatening Hemorrhage CAT Scans of Cerebral Hemorrhage Intracerebral Hemorrhage: Limited Data Kcentra: FDA approval Safety: Meta-analysis Anticoagulation Antidotes Dose Differences: AFib vs VTE NOACS in Clinical Practice Continuing role for warfarin?

Return to:

The American Journal of Medicine

« Prev

Next »
Click Figure to Enlarge

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

The American Journal of Medicine

Print This Page

Treatment of Intracerebral Hemorrhage: Limited Data for Warfarin

It is important to emphasize that with warfarin, we are very good at reversing the INR, but this may not be the same as actually changing the outcome of the patient once one of these hemorrhages occurs.

Meta-analyses and systematic reviews have shown that there is really no evidence from randomized trials of warfarin therapy that rapid reversal of anticoagulation in patients with an acute anticoagulation-associated intracerebral hemorrhage will improve functional outcome. I believe that it is important to embrace the concept of functional outcome in addition to reversing the INR.

Hylek EM. Am J Med 2014; 00.